Analyzing Real-World Adverse Events of Spironolactone with the FAERS Database

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

In this retrospective study, the incidence of hyperkalaemia within the first year of spironolactone use was assessed among women over 65 with female-pattern hair loss, highlighting a potential safety concern.

This study reports that spironolactone use was associated with a decreased risk of developing rosacea compared to other diuretics, particularly in current users without previous androgenic skin disease diagnoses.